scholarly journals Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Aradeep Chatterjee ◽  
Jaydip Biswas ◽  
Ashim Chatterjee ◽  
Sudin Bhattacharya ◽  
Bishnu Mukhopadhyay ◽  
...  
Keyword(s):  
Gall Bladder ◽  
Cancer Treatment ◽  
Tumor Response ◽  
Final Analysis ◽  
Controlled Clinical Trial ◽  
Prospective Clinical Study ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Scientific Exploration ◽  
Liver Cancers

We prospectively studied the clinical efficacy of an alternative cancer treatment “Psorinum Therapy” in treating stomach, gall bladder, pancreatic and liver cancers. Our study was observational, open level and single arm. The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02 ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. 158 participants (42 of stomach, 40 of gall bladder, 44 of pancreatic, 32 of liver) were included in the final analysis of the study. Complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. Double-blind randomized controlled clinical trial should be conducted for further scientific exploration of this alternative cancer treatment.

scholarly journals The influence of water intake on waiting time prior to uroflowmetry: a prospective, randomized, double-blind trial

2017 ◽  
Vol 26 (3) ◽  
pp. 212-7
Author(s):  
Nur Rasyid ◽  
Donny E. Putra ◽  
Widi Atmoko ◽  
Adianti Khadijah ◽  
Dyandra Parikesit ◽  
...  
Keyword(s):  
Water Intake ◽  
Waiting Time ◽  
Final Analysis ◽  
Study Groups ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Mean Waiting Time ◽  
Influence Of Water ◽  
Superiority Trial ◽  
Male Patients

Background: In uroflowmetry examination, patients are usually instructed to intake a large volume of water and wait until the bladder is full. The association between the volume of water intake and the waiting time before uroflowmetry is unknown. The aim of this study is to investigate the relationship between the volume of water intake and the waiting time prior to uroflowmetry.Methods: This trial was designed as a randomized, researchers, caregivers and patients blinded, superiority trial with three parallel groups and primary endpoint of waiting time prior to the uroflowmetry study based on the volume of patients’ water intake. Randomization was performed by block randomization with a 1:1:1 allocation. Patients scheduled for uroflowmetry at the Urology Clinic of Cipto Mangunkusumo Hospital were enrolled from March 2013 until December 2013. The eligibility criteria were male patients with ages above 50 years and body mass index 18.5–24.9 kg/m2.Results: A total of 83 patients was randomly assigned into 3 study groups: 300 ml (28 patients), 400 ml (28 patients), and 500 ml (27 patients). All patients were included in final analysis. Mean waiting time were 85.1±59.8 min, 107.2±70.4 min, and 66±28.4 min for patients intake 300, 400, and 500 ml of water respectively (p=0.07). The final bladder volumes for three groups were statistically different (262.4±130.8 ml, 289.4±126.2 ml, 359.2±137 ml; p=0.02).Conclusion: The volume water intake of 300–500 ml did not affect waiting time before uroflowmetry. Increasing water intake at least 500 ml added the final bladder volume and shorter the waiting time.

Effects of individually chosen homoeopathic medicines on recurrent URTI in children

1996 ◽  
Vol 85 (01) ◽  
pp. 4-14
Author(s):  
J. Blommers ◽  
D.J. Kuik ◽  
L. Feenstra ◽  
P.D. Bezemer ◽  
E.S.M. De Lange-De Klerk
Keyword(s):  
Clinical Trial ◽  
University Hospital ◽  
Controlled Clinical Trial ◽  
Upper Respiratory Tract ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Upper Respiratory ◽  
The University ◽  
Current Standards

AbstractThe effects of homoeopathic medicines on children suffering from recurrent upper respiratory tract infection (URTI) were studied in a randomized double-blind placebo-controlled clinical trial conducted at the paediatric outpatients department of the university hospital of the Vrije Universiteit in Amsterdam from 1987 to 1992.The study was designed to meet both the requirements of proper homoeopathic practice and the current standards of a clinical trial. The purpose of a randomized placebo-controlled double-blind trial is to identify the effects of the agents under investigation by equalizing the effects of other factors that may influence outcome.The object of the trial, eligibility criteria, follow-up period, treatments and concurrent interventions, data collection and effect measures are discussed in the light of homoeopathic thinking.

A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3050-3050 ◽  
Author(s):  
A. Chatterjee ◽  
S. Bhattacharya ◽  
A. K. Chatterjee ◽  
J. Biswas ◽  
B. Mukhopadhyay
Keyword(s):  
Clinical Study ◽  
Side Effects ◽  
Cancer Treatment ◽  
Late Stage ◽  
Tumor Response ◽  
Stage Ii ◽  
Stage Iii ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Liver Cancers

3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, ‘psorinum therapy,‘ in treating liver, gall bladder, pancreatic, and stomach cancers. The primary outcome measures of the study were (1) to assess the radiological tumor response; (2) to assess how many participants survived at least 1 year, 2 years, 3 years, 4 years, and finally, 5 years after the beginning of the study. The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any. Methods: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares. Results: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study. According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV. According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. 126 (79.75%) of them survived at least 1 year, 99 (62.66%) of them survived at least 2 years, 87 (55.06%) of them survived at least 3 years, 76 (48.10%) of them survived at least 4 years, and 62 (39.24%) of them survived at least 5 years. These participants did not receive any other conventional or investigational cancer treatments. The participants report no side effects from the drug psorinum. Conclusions: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers. Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment. No significant financial relationships to disclose.

scholarly journals Metabolic and Clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind randomized placebo-controlled clinical trial

2020 ◽  
Author(s):  
Saber Jafari-Maskouni ◽  
Mansour Shahraki ◽  
Milad Daneshi-Maskooni ◽  
Alireza Dashipour ◽  
Ali Shamsi-Goushki ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Glucose ◽  
Lipoprotein Cholesterol ◽  
Controlled Clinical Trial ◽  
Model Assessment ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Bunium Persicum ◽  
Clinical Responses

Abstract Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients.Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR), and Body Mass Index (BMI) were also calculated.Results: In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P>0.05).Conclusion: BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752

scholarly journals Metabolic and Clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind randomized placebo-controlled clinical trial

2020 ◽  
Author(s):  
Saber Jafari-Maskouni ◽  
Mansour Shahraki ◽  
Milad Daneshi-Maskooni ◽  
Alireza Dashipour ◽  
Ali Shamsi-Goushki ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Glucose ◽  
Lipoprotein Cholesterol ◽  
Controlled Clinical Trial ◽  
Model Assessment ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Bunium Persicum ◽  
Clinical Responses

Abstract Background : Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients. Methods : Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR) and Body Mass Index (BMI) were also calculated. Results : In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL,WC and Nesfatin-1 were not significant (P>0.05). Conclusion : BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results. Trial Registration : Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752

scholarly journals Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial

2021 ◽  
Author(s):  
Ravi K. Amaravadi ◽  
Lydia Giles ◽  
Mary Carberry ◽  
Matthew C. Hyman ◽  
Ian Frank ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Secondary Infection ◽  
University Of Pennsylvania ◽  
Symptom Improvement ◽  
Controlled Clinical Trial ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Link Type ◽  
Testing Center ◽  
At Home

ABSTRACTBackgroundOlder patients are at risk of increased morbidity and mortality from COVID-19 disease due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There are few effective treatments for outpatients with COVID-19.ObjectiveTo evaluate the efficacy of hydroxychloroquine to reduce time in quarantine for symptomatic ≥40 years-old COVID-19 patients.DesignA randomized, double-blind, placebo-controlled clinical trial.SettingOutpatients with polymerase chain reaction confirmed COVID-19 at a University of Pennsylvania affiliated testing center between April 15, 2020 and, July 14, 2020.ParticipantsOut of 5511 SARS-CoV-2 positive patients, 1072 met initial eligibility criteria for telephone-based recruitment, but only 34 subjects were able to be randomized.InterventionsHydroxychloroquine 400 mg per twice daily (n=17) or matching placebo (n=17), taken orally for up to 14 days.MeasurementsThe primary outcome was the time to release from quarantine. Secondary outcomes included the participant-reported secondary infection of co-inhabitants, hospitalization, treatment-related adverse events, time to symptom improvement, and incidence of cardiac arrhythmia.ResultsThe median time to release from quarantine for HCQ-treated vs. placebo-treated participants was 8 days (range 4-19 days) vs. 11 days (4-18 days); z-score +0.58, p=n.s. This did not meet the pre-specified criteria for early termination, however, this study was terminated early due to lack of feasibility. There was no mortality in either study arm.LimitationSince this study was terminated early due to a lack of feasibility, no conclusion can be made about the efficacy of hydroxychloroquine as a treatment for COVID-19 patients 40 years of age or older quarantined at home.ConclusionThe design of this remotely conducted study could guide testing of other more promising agents during the COVID-19 pandemic.Trial registrationClinicaltrials.gov identifier: NCT04329923

scholarly journals Clinical Behaviour and Marginal Sealing of Bulk-Fill Resin Composite Restorations Using Light Amplified High-Intensity LEDs Curing: A Randomized Controlled Clinical Trial

2019 ◽  
Vol 7 (8) ◽  
pp. 1360-1368 ◽  
Author(s):  
Shereen Essameldin Fahim ◽  
Mostafa Abdelhamid Mostafa ◽  
Mohsen Hussein Abi-Elhassan ◽  
HebatAllah Mohamed Taher
Keyword(s):  
High Intensity ◽  
Clinical Performance ◽  
Clinical Success ◽  
Resin Composite ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Composite Restorations

BACKGROUND: Delivering sufficient intensity output of curing lights is mandatory to ensure optimum cure and clinical success of bulk-fill resin composite restorations and to avoid undesirable clinical outcomes. AIM: To evaluate the effectiveness of using light amplified high intensity LED curing on the clinical performance and marginal sealing of posterior bulk-fill resin composite restorations. MATERIAL AND METHODS: This study was designed as a randomised, controlled, double-blind, Unicenter, parallel, two arms, superiority trial with 1:1 allocation ratio. Adult patients who required posterior tooth-coloured restorations were asked to participate in this trial. All participants signed written informed consent after being completely aware of the settings of the study. The participants who fulfilled the eligibility criteria were divided into two groups according to the type of light curing mode used. Adhesive compound proximal cavities were prepared. All restorative materials were applied according to the respective manufacturer’s instructions. Assessments of the restorations were done at baseline (one week after placement of the restoration), after 6 months and after 12 months using the modified US Public Health Service (USPHS) criteria. For quantitative assessment of the marginal sealing, resin replicas were analysed using scanning electron microscopy. Statistical analysis was done using Chi-square, Mann Whitney, independent t-test and dependent t-tests. RESULTS: There were no statistical differences between the two groups for the tested clinical parameters along the study periods. For marginal analysis, there were no statistical differences between the intervention and control group at baseline and six months (p-value = 0.347 and 0.516) respectively. At 12 months the control group showed statistically significant higher percentages (p-value = 0.031). CONCLUSION: Light amplified high-intensity curing units have clinical performance comparable with the conventional LED.

The effects of Bunium Persicum (Black Caraway) supplementation on glycemic indices, lipid profiles and serum levels of nesfatin-1 in overweight and obese patients with type 2 diabetes: a double-blind randomized placebo-controlled clinical trial

2020 ◽  
Author(s):  
Saber Jafari-Maskouni ◽  
Mansour Shahraki ◽  
Milad Daneshi-Maskooni ◽  
Alireza Dashipour ◽  
Ali Shamsi-Goushki ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Serum Glucose ◽  
Lipoprotein Cholesterol ◽  
Controlled Clinical Trial ◽  
Model Assessment ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Bunium Persicum

Abstract Background: Diabetes mellitus is the most common metabolic disorder worldwide. Our aim was to determine the effects of bunium persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels among overweight or obese T2DM patients.Methods: The place of participant recruitment was the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups as BP (n=30) or placebo (n=30). The supplementation was one 1000 mg capsules 2 times/day BP with launch and dinner for 8 weeks. Bodyweight, Waist circumference, serum nesfatin-1, fasting blood sugar (FBS), insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR) and Body Mass Index (BMI) were also calculated.Results: In comparison with placebo, PB significantly increased QUICKI and decreased FBS, HOMA-IR, BMI and WC (P<0.05). At the end of the study after adjustment for confounders, the changes were similar (P<0.05) with an exception for QUICKI which had a trend (P=0.054) and WC (P > 0.05). The differences in the FBI, TG, TC, LDL, HDL and Nesfatin-1 were not significant (P>0.05).Conclusion: PB supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.

Sign in / Sign up

Export Citation Format

Share Document